RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oxford Biomedica Stock

Oxford Biomedica Revenue 2025

Oxford Biomedica Revenue

168.79 M GBP

Ticker

OXB.L

ISIN

GB00BDFBVT43

WKN

A2JLRX

In 2025, Oxford Biomedica's sales reached 168.79 M GBP, a 31.05% difference from the 128.8 M GBP sales recorded in the previous year.

The Oxford Biomedica Revenue history

YEARREVENUE (undefined GBP)GROSS MARGIN (%)
2030e313.8916,89
2029e276.2119,20
2028e283.6118,70
2027e252.321,02
2026e216.3824,50
2025e168.7931,41
2024128.841,17
202389.5444,37
2022139.9949,42
2021142.857,87
202087.7352,52
201964.0644,24
201866.7865,91
201737.5950,94
201627.7857,39
201515.9163,30
201413.6267,57
20135.3878,81
20127.7691,37
20117.7292,75
201011.15105,38
200919.1297,70
200818.3992,99
20077.2293,77
20060.76100,00
20050.826465,98

Oxford Biomedica Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Oxford Biomedica, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oxford Biomedica from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oxford Biomedica’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Oxford Biomedica. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Oxford Biomedica’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Oxford Biomedica’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oxford Biomedica’s growth potential.

Oxford Biomedica Revenue, EBIT and net profit per share

DateOxford Biomedica RevenueOxford Biomedica EBITOxford Biomedica Net Income
2030e313.89 M undefined0 undefined0 undefined
2029e276.21 M undefined71.1 M undefined0 undefined
2028e283.61 M undefined22.05 M undefined46.76 M undefined
2027e252.3 M undefined20.16 M undefined8.22 M undefined
2026e216.38 M undefined3.01 M undefined-13.89 M undefined
2025e168.79 M undefined-23.44 M undefined-34.89 M undefined
2024128.8 M undefined-39.31 M undefined-43.19 M undefined
202389.54 M undefined-85.98 M undefined-157.49 M undefined
2022139.99 M undefined-51.56 M undefined-39.16 M undefined
2021142.8 M undefined20.93 M undefined19.01 M undefined
202087.73 M undefined-4.86 M undefined-6.25 M undefined
201964.06 M undefined-12.58 M undefined-16.07 M undefined
201866.78 M undefined7.93 M undefined7.54 M undefined
201737.59 M undefined-7.97 M undefined-9.02 M undefined
201627.78 M undefined-11.31 M undefined-16.64 M undefined
201515.91 M undefined-14.08 M undefined-13.02 M undefined
201413.62 M undefined-10.61 M undefined-8.66 M undefined
20135.38 M undefined-12.82 M undefined-11.1 M undefined
20127.76 M undefined-10.49 M undefined-8.73 M undefined
20117.72 M undefined-11.3 M undefined-12.63 M undefined
201011.15 M undefined-8.06 M undefined-10.29 M undefined
200919.12 M undefined-2.17 M undefined-3.52 M undefined
200818.39 M undefined-9.11 M undefined-10.04 M undefined
20077.22 M undefined-19.49 M undefined-15.29 M undefined
2006760,000 undefined-21.1 M undefined-17.63 M undefined
2005820,000 undefined-11.23 M undefined-9.09 M undefined

Oxford Biomedica stock margins

The Oxford Biomedica margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oxford Biomedica. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oxford Biomedica.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Oxford Biomedica's sales revenue. A higher gross margin percentage indicates that the Oxford Biomedica retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Oxford Biomedica's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Oxford Biomedica's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oxford Biomedica's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oxford Biomedica. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oxford Biomedica's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Oxford Biomedica Margin History

Oxford Biomedica Gross marginOxford Biomedica Profit marginOxford Biomedica EBIT marginOxford Biomedica Profit margin
2030e41.17 %0 %0 %
2029e41.17 %25.74 %0 %
2028e41.17 %7.77 %16.49 %
2027e41.17 %7.99 %3.26 %
2026e41.17 %1.39 %-6.42 %
2025e41.17 %-13.89 %-20.67 %
202441.17 %-30.52 %-33.53 %
202344.37 %-96.03 %-175.89 %
202249.42 %-36.83 %-27.97 %
202157.87 %14.66 %13.31 %
202052.52 %-5.54 %-7.12 %
201944.24 %-19.64 %-25.08 %
201865.91 %11.88 %11.29 %
201750.94 %-21.19 %-23.99 %
201657.39 %-40.73 %-59.91 %
201563.3 %-88.52 %-81.83 %
201467.57 %-77.93 %-63.6 %
201378.81 %-238.29 %-206.32 %
201291.37 %-135.18 %-112.5 %
201192.75 %-146.37 %-163.6 %
2010105.38 %-72.29 %-92.29 %
200997.7 %-11.35 %-18.41 %
200892.99 %-49.54 %-54.59 %
200793.77 %-269.94 %-211.77 %
2006100 %-2,776.32 %-2,319.74 %
200541.17 %-1,369.51 %-1,108.54 %

Oxford Biomedica Aktienanalyse

What does Oxford Biomedica do?

Oxford BioMedica PLC is a biopharmaceutical company based in Oxford, England. The company was founded in 1995 and has since become a leading provider of gene therapy products. The company's business model is to develop, produce, and market gene therapies for rare diseases and cancer. Oxford BioMedica utilizes modern technologies, such as viral vectors, to introduce genetic material into diseased cells and correct their function. One of the company's main areas of focus is the development of gene therapies for rare diseases. Oxford BioMedica has several promising products in this field, including gene therapies for metabolic disorders, muscular diseases, and eye diseases. Another important area for the company is the development of cancer immunotherapies. Oxford BioMedica is working on the development of gene therapies that activate the body's immune system to specifically target cancer cells. Among the products that Oxford BioMedica has already brought to market is the gene therapy product Strimvelis, which is used to treat severe combined immunodeficiency (SCID). Through treatment with Strimvelis, children with SCID can lead a normal life and are no longer confined to sterile environments. Another well-known product from Oxford BioMedica is the gene therapy product OXB-102, which is being tested in phase III clinical trials for the treatment of Parkinson's disease. In this therapy, a viral vector is used to correct a genetic mutation in the affected brain cells and alleviate the symptoms of Parkinson's. In recent years, Oxford BioMedica has also formed significant partnerships with major pharmaceutical and biotech companies such as Novartis, Sanofi, and Bioverativ to further develop and bring its gene therapy technology and products to market. Overall, Oxford BioMedica is a leading company in the field of gene therapy. With a strong pipeline of promising products and significant partnerships with the pharmaceutical industry, the company is well positioned to continue growing and contribute to the cure of diseases. Oxford Biomedica ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Oxford Biomedica's Sales Figures

The sales figures of Oxford Biomedica originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Oxford Biomedica’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Oxford Biomedica's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Oxford Biomedica’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Oxford Biomedica stock

How much revenue did Oxford Biomedica generate this year?

Oxford Biomedica has achieved a revenue of 168.79 M GBP this year.

How much was the turnover of the company Oxford Biomedica compared to the previous year?

The revenue of Oxford Biomedica has increased by 31.05% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Oxford Biomedica?

The revenue of Oxford Biomedica is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Oxford Biomedica measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Oxford Biomedica so important for investors?

The revenue of Oxford Biomedica is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Oxford Biomedica pay?

Over the past 12 months, Oxford Biomedica paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oxford Biomedica is expected to pay a dividend of 0 GBP.

What is the dividend yield of Oxford Biomedica?

The current dividend yield of Oxford Biomedica is .

When does Oxford Biomedica pay dividends?

Oxford Biomedica pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oxford Biomedica?

Oxford Biomedica paid dividends every year for the past 0 years.

What is the dividend of Oxford Biomedica?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oxford Biomedica located?

Oxford Biomedica is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oxford Biomedica kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oxford Biomedica from 7/25/2025 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 7/25/2025.

When did Oxford Biomedica pay the last dividend?

The last dividend was paid out on 7/25/2025.

What was the dividend of Oxford Biomedica in the year 2024?

In the year 2024, Oxford Biomedica distributed 0 GBP as dividends.

In which currency does Oxford Biomedica pay out the dividend?

The dividends of Oxford Biomedica are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Oxford Biomedica stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Oxford Biomedica

Our stock analysis for Oxford Biomedica Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oxford Biomedica Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.